

Regulated information - inside information

Nazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET

## **Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions**

Fagron, the leading global player in pharmaceutical compounding, announces that the Brazilian competition authority, CADE, has granted clearance for the previously announced acquisitions of Purifarma and Injeplast in Brazil.

The clearances represent an important step forward in executing Fagron's disciplined M&A strategy in Latin America. The transactions will broaden Fagron's portfolio and capabilities in Brazil, supporting the Group's ambition to build a scalable, high-quality platform aligned with its long-term growth objectives.

**Purifarma** operates a highly concentrated Essentials portfolio at very large volumes, presenting significant potential to improve profitability within 18 months post-closing through enhanced product portfolio and brands expansion, as well as increased operational leverage and procurement savings. In addition, the scale-up is expected to generate procurement benefits not only across Latin America but throughout our entire global footprint.

**Injeplast** will further strengthen Fagron's vertical integration by producing high-quality packaging solutions and efficient manufacturing processes, supporting our Essentials strategy by broadening our product portfolio and customer base in Latin America as well as other regions.

Completion of the acquisitions remains subject to customary closing conditions and completion of certain local corporate and contractual formalities.

**Rafael Padilla, CEO of Fagron, commented:**

*"CADE's approvals allow us to progress towards closing Purifarma and Injeplast. These acquisitions strengthen our leadership position in Brazil and complement our strategy to combine targeted M&A with operational excellence while maintain financial discipline."*



### **Financial calendar 2025**

9 October 2025

Trading update third quarter 2025

Results and trading updates are published at 7.00 AM CET.

### **Further information**

Ignacio Artola

Global Investor Relations Leader

Tel. +34 670385795

[ignacio.artola@fagron.com](mailto:ignacio.artola@fagron.com)

### **About Fagron**

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed through the Dutch company Fagron BV. Fagron BV's head office is located in Rotterdam.

### **Important information regarding forward-looking statements**

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

*In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.*